Immunome, Inc. (IMNM) Research

Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.

Market snapshot

Symbol
IMNM
Price
$18.74
Day change
+1.13%
Market cap
$1.8B
P/E ratio
-9.44x
52-week range
7.96-27.65
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$36.50

Peer companies

  • AbCellera Biologics Inc. (ABCL)
  • Biohaven Ltd. (BHVN)
  • Celldex Therapeutics, Inc. (CLDX)
  • Maze Therapeutics, Inc. (MAZE)
  • Intellia Therapeutics, Inc. (NTLA)
  • Pharvaris N.V. (PHVS)
  • Spyre Therapeutics, Inc. (SYRE)
  • Upstream Bio, Inc. (UPB)

Recent insider activity

  • Rosett Max — M-Exempt (60000 shares) on 2026-06-15
  • Rosett Max — S-Sale (60000 shares) on 2026-06-15
  • Rosett Max — M-Exempt (60000 shares) on 2026-06-15
  • SWAIN SANDRA M — A-Award (9897 shares) on 2026-06-10
  • WAGENHEIM PHILIP — A-Award (9897 shares) on 2026-06-10

Open Immunome, Inc. (IMNM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.